New hope for halting rare brain disease
NCT ID NCT05662111
Summary
This study is testing whether a drug called etidronate can slow down or stop the buildup of harmful calcium deposits in the brains of people with Fahr's disease or syndrome. It will enroll 98 adults with the condition to see if the drug improves thinking, movement, and daily life over 18 months. This is the first controlled trial for a disease that currently has no treatments to stop its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAHR DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College London Hospital
NOT_YET_RECRUITINGLondon, United Kingdom
Contact
Contact Phone: •••-•••-••••
-
University Medical Center Utrecht
RECRUITINGUtrecht, Utrecht, 3584 CX, Netherlands
Contact
Conditions
Explore the condition pages connected to this study.